alexa Supra AntigenTM Technology Platform: Manufacturing And Development Of Vaccines For The Treatment Of Alzheimer Disease | 9849
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Pedro Reis, P. Donati, A. Pfeifer, and A. Muhs
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
A lzheimer?s disease (AD), the most common form of dementia, is characterized by pathological Amyloid beta (Aβ) deposition into plaques and neurofibrillary tangles due to aggregation of hyperphosphorylated Tau protein in the brain. The benchmark for AD vaccines targeting Aβ, is the generation of antibodies without the introduction of antigen specific T-cells, which have been reported to cross the blood-brain-barrier and cause encephalitis in 6% of AD patients receiving anti-Aβ vaccine. We developed a liposome vaccine platform technology that combines (i) antigens lacking T-cell epitopes, (ii) adjuvant signaling via TLR stimulation and (iii) B-cell receptor cross-linking by repetitive assembly of epitopes. AC Immune has developed its own vaccine manufacturing technology in order to make it easily up-scalable and compatible with cGMP principals. Our present work highlights AC Immune?s development approach for bringing an AD vaccine under clinical environment. The rationale for process development was to simplify the process, improve the homogeneity of the liposomes, reduce manufacturing time and make it easier to scale the process. Our data indicates that AC Immune?s manufacturing strategy is suitable for the preparation of drug product for preclinical and clinical studies at 100-1,000 mL scale. The following additional comments can be made. i. The preparation of the liposomes appears flexible and robust, and should be readily scalable ii. It is likely that the quality of the peptide raw material, and perhaps its tendency to aggregate may have an impact on the level of protein incorporation into the vesicles, the homogeneity of the liposomes and presence of aggregates. The level of peptide incorporation into the liposomes was generally quite high and the level of unincorporated peptide was low iii. The current manufacturing strategy appears suitable for preparation of intermediate (100-1,000 mL) batches; however, large scale batches may use an in-line mixing system to mix the protein with the vesicles. Studies to optimize the detergent to protein ratio, detergent to lipid ratio, and lipid concentration at the time of peptide reconstitution may also be required at this time iv. Clarifying filtration provides a useful strategy to improve the sterile filtration process, and remove some of the aggregates and/or larger particles that are present in the formulation
Biography
Pedro Reis pursued his Ph.D. on Biophysics in 2008 at Chalmers University of Technology, Sweden. Afterwards, he was appointed as Primer Researcher at Baylor College of Medicine, Houston and at UNIL?s Biochemistry Department, Switzerland. Since August 2009, Pedro Reis has been working as a project leader of vaccine manufacturing at AC Immune SA, which is a Swiss-based biopharmaceutical company and a leader in Alzheimer?s disease drug development. AC Immune SA has been developing innovative therapeutics with ?best in class? potential against Alzheimer?s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version